Bernhard Scheiner
YOU?
Author Swipe
View article: Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease Open
Background Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is characterised by hepatic fibrosis and (sinusoidal) basement membrane development contributing to portal hypertension (PH) and clinical complicati…
View article: Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab Open
Spontaneously immunogenic hepatocellular carcinoma (HCC), identified by a dense immune cell infiltrate (ICI), responds better to immunotherapy, although no validated biomarker exists to identify these cases. We used machine learning (ML) t…
View article: “Advancing Clinical Trial Design and Patient Care in Hepatocellular Carcinoma”
“Advancing Clinical Trial Design and Patient Care in Hepatocellular Carcinoma” Open
View article: Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study Open
Background & Aims: Atezolizumab plus bevacizumab (A+B) is a standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). However, optimal sequencing strategies after A+B failure remain undefined. Methods: LEVIATHAN…
View article: Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma Open
Unlike other solid tumours, the prognosis of patients with advanced hepatocellular carcinoma (HCC) is dually influenced by tumour progression and liver dysfunction. Accumulating evidence suggests that clinically evident hepatic decompensat…
View article: Non‐Invasive Stratification of Portal Hypertension in Patients With <scp>BCR</scp>::<scp>ABL1</scp>‐Negative Myeloproliferative Neoplasms
Non‐Invasive Stratification of Portal Hypertension in Patients With <span>BCR</span>::<span>ABL1</span>‐Negative Myeloproliferative Neoplasms Open
Background & Aims The course of BCR::ABL1‐negative myeloproliferative neoplasms (MPN) is frequently complicated by thromboembolic events in the splanchnic venous system, resulting in portal hypertension (PH). Therefore, the introduction of…
View article: Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study
Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study Open
Background The gut microbiota is often altered in chronic liver diseases and hepatocellular carcinoma (HCC), and increasing evidence suggests that it may influence response to cancer immunotherapy. Strategies to modulate the gut microbiome…
View article: ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab Open
A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.
View article: Elevated Hepatic Copper Content in Porto‐Sinusoidal Vascular Disorder (<scp>PSVD</scp>): <i>Leading Down a Wrong Track</i>
Elevated Hepatic Copper Content in Porto‐Sinusoidal Vascular Disorder (<span>PSVD</span>): <i>Leading Down a Wrong Track</i> Open
Background and Aims Porto‐sinusoidal vascular disorder (PSVD) is a rare vascular liver disorder characterised by specific histological findings in the absence of cirrhosis, which is poorly understood in terms of pathophysiology. While elev…
View article: Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab Open
The CABLE score allows estimation of the prognosis of patients with unresectable hepatocellular carcinoma undergoing first-line immunotherapy with atezolizumab and bevacizumab at an individual level using our web-based calculator. This fea…
View article: The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma
The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma Open
Background and Aim: Age and biological sex are risk factors for hepatocellular carcinoma (HCC) occurrence, but their impact on overall survival (OS) is a matter of debate. This study aims to investigate how sex and age at diagnosis, along …
View article: Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) Open
Background Cancer cachexia can impact prognosis, cause resistance to anticancer treatments and affect the tolerability of treatments. This study aims to identify hepatocellular carcinoma (HCC) with cachexia by characterizing longitudinal b…
View article: Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort Open
Background: Immunotherapy-based combinations are currently the standard of care in the systemic treatment of patients with HCC. Recent studies have reported unexpectedly long survival with lenvatinib (LEN), supporting its use in first-line…
View article: Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab Open
View article: Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply Open
LINKED CONTENT This article is linked to Dominik et al papers. To view these articles, visit https://doi.org/10.1111/apt.18179 and https://doi.org/10.1111/apt.18293 .
View article: Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality Open
Summary Background and Aims We aimed to characterise insulin‐like growth factor‐1 (IGF‐1) signalling in patients with advanced chronic liver disease (ACLD). Methods Consecutive patients undergoing hepatic venous pressure gradient [HVPG] me…
View article: Metabolomic profiles differentiate between porto-sinusoidal vascular disorder, cirrhosis, and healthy individuals
Metabolomic profiles differentiate between porto-sinusoidal vascular disorder, cirrhosis, and healthy individuals Open
View article: Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome Open
View article: Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma Open
In summary, this study demonstrates comparable mOS for AILD-HCC patients undergoing local and systemic treatments, with better tolerability than HCC of other causes. TKIs remain important therapeutic options for AILD-HCC patients, particul…
View article: Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease Open
Summary Background and Aims Zinc and selenium are essential trace elements involved in important (patho)physiological processes. The prevalence and prognostic implications of zinc and selenium deficiency in patients with advanced chronic l…
View article: Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction Open
Importance Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated. Objective To evaluate the association of…
View article: Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma
Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma Open
Background and Aims Deterioration of liver function is a leading cause of death in patients with advanced hepatocellular carcinoma (HCC). We evaluated the impact of immune checkpoint inhibitor (ICI)‐treatment on liver function and outcomes…
View article: Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial
Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial Open
Introduction: The tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib represent the first-line systemic therapy of choice for patients with hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). Under sorafenib …
View article: Anaemia is independently associated with mortality in patients with hepatocellular carcinoma
Anaemia is independently associated with mortality in patients with hepatocellular carcinoma Open
View article: Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure
Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure Open
CytoSorb is a hemoadsorptive column used to remove high concentrations of proinflammatory cytokines in septic shock. Data on CytoSorb application in acute-on-chronic liver failure (ACLF) is lacking. This retrospective observational study a…
View article: The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden Open
Introduction: As tumour response rates are increasingly demonstrated in early-phase cancer trials (EPCT), optimal patient selection and accurate prognostication are paramount. Hammersmith Score (HS), a simple prognostic index derived on ro…
View article: Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events Open
The inhibition of VEGF by current first-line therapies for HCC, such as atezolizumab/bevacizumab or lenvatinib, may be associated with the risk of bleeding and thromboembolic events. Studies comparing the incidence of these side effects be…
View article: Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease
Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease Open
Summary Background and Aims The prognostic performance of von Willebrand factor (VWF) may vary across clinical stages of advanced chronic liver disease (ACLD). Therefore, we investigated the evolution of VWF and other biomarkers throughout…
View article: Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion
Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion Open
Background & aims The value of bleeding prophylaxis and anticoagulation in patients with hepatocellular carcinoma (HCC) and macrovascular tumour invasion (MVI) is unclear. We evaluated the impact of anticoagulation on thrombosis progressio…
View article: A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma Open